Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N B Glazer

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The American Journal of Nursing|December 31, 1997
Considering HumalogN B Glazer
Clinical Therapeutics|April 11, 2001
A comprehensive review of the antidiabetic agent rosiglitazoneN B Glazer, W W Cheatham
BMJ (Clinical Research Ed.)|February 13, 2001
Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4N B Glazer, W W Cheatham
The Diabetes Educator|April 25, 2000
The latest developments in insulin injection devicesK E Robertson, N B Glazer, R K Campbell
International Journal of Clinical Practice|June 21, 2002
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapyJ Rosenstock, D Einhorn, K Hershon, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 7, 1999
Safety of insulin lispro: pooled data from clinical trialsN B Glazer, S Zalani, J H Anderson, et al.
Coronary Artery Disease|August 9, 2001
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitusS Rosenblatt, B Miskin, N B Glazer, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|February 24, 2001
Good publication practice guideline for pharmaceutical companiesE Wager, J A Tumas, E A Field, et al.
JAMA|June 6, 2000
Improving the conduct and reporting of clinical trialsE Wager, J A Tumas, E A Field, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The American Journal of Nursing|December 31, 1997
Considering HumalogN B Glazer
Clinical Therapeutics|April 11, 2001
A comprehensive review of the antidiabetic agent rosiglitazoneN B Glazer, W W Cheatham
BMJ (Clinical Research Ed.)|February 13, 2001
Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4N B Glazer, W W Cheatham
The Diabetes Educator|April 25, 2000
The latest developments in insulin injection devicesK E Robertson, N B Glazer, R K Campbell
International Journal of Clinical Practice|June 21, 2002
Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapyJ Rosenstock, D Einhorn, K Hershon, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 7, 1999
Safety of insulin lispro: pooled data from clinical trialsN B Glazer, S Zalani, J H Anderson, et al.
Coronary Artery Disease|August 9, 2001
The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitusS Rosenblatt, B Miskin, N B Glazer, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|February 24, 2001
Good publication practice guideline for pharmaceutical companiesE Wager, J A Tumas, E A Field, et al.
JAMA|June 6, 2000
Improving the conduct and reporting of clinical trialsE Wager, J A Tumas, E A Field, et al.
Pageof 1